At the time of writing, Mereo Biopharma Group Plc ADR [MREO] stock is trading at $2.00, up 5.26%. An important factor to consider is whether the stock is rising or falling in short-term value. The MREO shares have gain 13.64% over the last week, with a monthly amount drifted -23.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mereo Biopharma Group Plc ADR [NASDAQ: MREO] stock has seen the most recent analyst activity on March 27, 2025, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $7. Previously, Jefferies started tracking the stock with Buy rating on December 06, 2024, and set its price target to $7. On June 13, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $8 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $4 as its price target on August 12, 2022. BTIG Research started tracking with a Buy rating for this stock on May 05, 2021, and assigned it a price target of $10. In a note dated April 05, 2021, Needham initiated an Buy rating and provided a target price of $10 on this stock.
For the past year, the stock price of Mereo Biopharma Group Plc ADR fluctuated between $1.58 and $5.02. Currently, Wall Street analysts expect the stock to reach $6.75 within the next 12 months. Mereo Biopharma Group Plc ADR [NASDAQ: MREO] shares were valued at $2.00 at the most recent close of the market. An investor can expect a potential return of 237.5% based on the average MREO price forecast.
Analyzing the MREO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.68 and Total Capital is -0.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9200 points at the first support level, and at 1.8500 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0400, and for the 2nd resistance point, it is at 2.0900.
Ratios To Look Out For
It is important to note that Mereo Biopharma Group Plc ADR [NASDAQ:MREO] has a current ratio of 5.40. On the other hand, the Quick Ratio is 5.40, and the Cash Ratio is 5.04.
Transactions by insiders
Recent insider trading involved Scots-Knight Denise, Chief Executive Officer, that happened on Sep 13 ’24 when 60046.0 shares were sold. Chief Executive Officer, Scots-Knight Denise completed a deal on Sep 12 ’24 to sell 28611.0 shares. Meanwhile, Chief Scientific Officer Lewicki John A. sold 10937.0 shares on Sep 13 ’24.
